Supplementary Figure 1. (A–F) The ratio of c-caspase3/β–actin, Bcl-2/Bax, HO-1/β–actin, NQO-1/β–actin, Nrf-2/β–actin and Keap-1/β–actin in ATDC5 cells under different treatments. (G–L) The ratio of c-caspase3/β–actin, Bcl-2/Bax, HO-1/β–actin, NQO-1/β–actin, Nrf-2/β–actin and Keap-1/β–actin in primary chondrocytes under different treatments. (M) The ratio of LC3II/LC3I in ATDC5 cells in different groups. (N) The ratio of autophagy marker proteins (p62 and Beclin-1) to β–actin in ATDC5 cells in different groups. ***p<0.001, **p<0.01, *p<0.05 (n = 3).
Supplementary Figure 2. (A) The ratio of LC3II/LC3I in ATDC5 cells under different treatments. (B) The ratio of autophagy marker proteins (p62 and Beclin-1) to β-actin in ATDC5 cells under different treatments. (C, D) The ratio of HO-1/β-actin, NQO-1/β-actin, Keap-1/β-actin, c-caspase3/β-actin and Bcl-2/Bax in ATDC5 cells under different treatments. (E) The ratio of p21/β-actin in ATDC5 cells in different groups. (F–K) The ratio of HO-1/β-actin, NQO-1/β-actin, Nrf-2/β-actin, Keap-1/β-actin, c-caspase3/β-actin and Bcl-2/Bax in ATDC5 cells under different treatments in the Lenti-NC group and Lenti-p21 group. ***p<0.001, **p<0.01, *p<0.05 (n = 3).